Paul J Young1, Sean M Bagshaw2, Andrew Forbes3, Alistair Nichol4, Stephen E Wright5, Rinaldo Bellomo4, Michael J Bailey4, Richard W Beasley6, Glenn M Eastwood7, Marino Festa8, David Gattas9, Frank van Haren10, Edward Litton11, Paul R Mouncey12, Leanlove Navarra6, David Pilcher4, Diane M Mackle6, Colin J McArthur6, Shay P McGuinness6, Manoj K Saxena13, Steve Webb4, Kathryn M Rowan12. 1. Intensive Care Unit, Wellington Regional Hospital, Wellington, New Zealand. Paul.Young@ccdhb.org.nz. 2. Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada. 3. Biostatistics Unit, Department of Epidemiology and Preventive Medicine at Monash University, Melbourne, Vic, Australia. 4. Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Vic, Australia. 5. Department of Perioperative and Critical Care, Freeman Hospital, Newcastle upon Tyne, United Kingdom. 6. Medical Research Institute of New Zealand, Wellington, New Zealand. 7. Intensive Care Unit, Austin Hospital, Melbourne, Vic, Australia. 8. Intensive Care Unit, Children's Hospital at Westmead, Sydney, NSW, Australia. 9. Intensive Care Unit, Royal Prince Alfred Hospital, Sydney, NSW, Australia. 10. Intensive Care Unit, Canberra Hospital, Canberra, ACT, Australia. 11. Intensive Care Unit, Fiona Stanley Hospital, Perth, WA, Australia. 12. Clinical Trials Unit, Intensive Care National Audit and Research Centre, London, United Kingdom. 13. The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.
Abstract
BACKGROUND: The balance of risks and benefits with using proton pump inhibitors (PPIs) versus histamine-2 receptor blockers (H2RB) for stress ulcer prophylaxis in patients who are invasively ventilated in the intensive care unit (ICU) is uncertain. OBJECTIVE: To describe the study protocol and statistical analysis plan for the Proton Pump Inhibitors versus Histamine-2 Receptor Blockers for Ulcer Prophylaxis Therapy in the Intensive Care Unit (PEPTIC) study. DESIGN, SETTING AND PARTICIPANTS: Protocol for a prospective, multicentre, randomised, open-label, cluster crossover, registry-embedded trial to be conducted in 50 ICUs in Australia, Canada, Ireland, New Zealand and the United Kingdom. The PEPTIC study will compare two approaches to stress ulcer prophylaxis in mechanically ventilated adults implemented at the level of the ICU. One approach is to use PPIs as the default therapy and the other approach is to use H2RBs as the default therapy when stress ulcer prophylaxis is prescribed. Each ICU, by random allocation, will use one approach for 6 months and will then switch to the opposite approach for the next 6 months. The PEPTIC study began recruitment in August 2016 and will complete recruitment in January 2019. MAIN OUTCOME MEASURES: The primary end point will be in-hospital mortality. Secondary outcomes include clinically significant upper gastrointestinal bleeding, Clostridium difficile infection, ICU length of stay and hospital length of stay. RESULTS AND CONCLUSIONS: The PEPTIC study will compare the effect on in-hospital mortality of implementing, at the level of the ICU, the use of PPI as the preferred agent for stress ulcer prophylaxis in mechanically ventilated adults in the ICU with using H2RB as the preferred agent. TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Registry (ANZCTRN 12616000481471).
RCT Entities:
BACKGROUND: The balance of risks and benefits with using proton pump inhibitors (PPIs) versus histamine-2 receptor blockers (H2RB) for stress ulcer prophylaxis in patients who are invasively ventilated in the intensive care unit (ICU) is uncertain. OBJECTIVE: To describe the study protocol and statistical analysis plan for the Proton Pump Inhibitors versus Histamine-2 Receptor Blockers for Ulcer Prophylaxis Therapy in the Intensive Care Unit (PEPTIC) study. DESIGN, SETTING AND PARTICIPANTS: Protocol for a prospective, multicentre, randomised, open-label, cluster crossover, registry-embedded trial to be conducted in 50 ICUs in Australia, Canada, Ireland, New Zealand and the United Kingdom. The PEPTIC study will compare two approaches to stress ulcer prophylaxis in mechanically ventilated adults implemented at the level of the ICU. One approach is to use PPIs as the default therapy and the other approach is to use H2RBs as the default therapy when stress ulcer prophylaxis is prescribed. Each ICU, by random allocation, will use one approach for 6 months and will then switch to the opposite approach for the next 6 months. The PEPTIC study began recruitment in August 2016 and will complete recruitment in January 2019. MAIN OUTCOME MEASURES: The primary end point will be in-hospital mortality. Secondary outcomes include clinically significant upper gastrointestinal bleeding, Clostridium difficileinfection, ICU length of stay and hospital length of stay. RESULTS AND CONCLUSIONS: The PEPTIC study will compare the effect on in-hospital mortality of implementing, at the level of the ICU, the use of PPI as the preferred agent for stress ulcer prophylaxis in mechanically ventilated adults in the ICU with using H2RB as the preferred agent. TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Registry (ANZCTRN 12616000481471).
Authors: Sean van Diepen; Tim Coulson; Xiaoming Wang; Dawn Opgenorth; Danny J Zuege; Jo Harris; Malik Agyemang; Daniel J Niven; Rinaldo Bellomo; Stephen E Wright; Paul J Young; Sean M Bagshaw Journal: Eur J Cardiothorac Surg Date: 2022-07-11 Impact factor: 4.534
Authors: Paul J Young; Sean M Bagshaw; Andrew B Forbes; Alistair D Nichol; Stephen E Wright; Michael Bailey; Rinaldo Bellomo; Richard Beasley; Kathy Brickell; Glenn M Eastwood; David J Gattas; Frank van Haren; Edward Litton; Diane M Mackle; Colin J McArthur; Shay P McGuinness; Paul R Mouncey; Leanlove Navarra; Dawn Opgenorth; David Pilcher; Manoj K Saxena; Steve A Webb; Daisy Wiley; Kathryn M Rowan Journal: JAMA Date: 2020-02-18 Impact factor: 56.272